A Phase 3 interventional study of Panitumumab and FOLFIRI in Metastatic Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 2nd largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2006, is one of 14 in phase 3, and was the 11th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
R-Pharm · Sites in Russia
Ages 18+
UNICANCER · Sites in France
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 2000; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,186 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 88 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 90 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Colorectal Neoplasms by Amgen: 2 open now, 2 under way, 1 of them phase 3. Of 38 finished, 24 (63%) have results posted.
Among the 40 studies in Colorectal Neoplasms by Amgen, this one has the largest enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2006, is one of 10 in phase 3, and was the 11th registered.
Amgen’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing panitumumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03087071M.D. Anderson Cancer CenterPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | 2027-01-31 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, from their registry updates:
Among Amgen’s 40 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
Drug: Panitumumab · Drug: FOLFIRI
Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
Drug: FOLFIRI
Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
Also known as: Vectibix®
FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
Progression-free Survival (PFS)
Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.
Time frame: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.
Overall Survival
Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date.
Time frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Percentage of Participants With an Objective Response
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.
Time frame: Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.
Time to Disease Progression
Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.
Time frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Duration of Response
Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.
Time frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Number of Participants With Adverse Events (AEs)
A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"
Time frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.
First patient enrolled 30 June 2006; Last patient enrolled 13 March 2008.
| Milestone | Panitumumab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Started | 591 | 595 |
| Received study drug | 588 | 593 |
| Completed | 470 | 490 |
| Not completed | 121 | 105 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Withdrawal by subject | 16 | 19 |
| Withdrew: Physician decision | 2 | 4 |
| Withdrew: Lost to follow-up | 17 | 17 |
| Withdrew: Protocol-specified criteria | 12 | 8 |
| Withdrew: Missing reason | 3 | 1 |
| Withdrew: Other | 46 | 40 |
| Withdrew: Ongoing | 20 | 13 |
Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.
| months | Wild-type KRAS - Panitumumab Plus FOLFIRI | Wild-type KRAS - FOLFIRI Alone | Mutant KRAS - Panitumumab Plus FOLFIRI | Mutant KRAS - FOLFIRI Alone |
|---|---|---|---|---|
| Progression-free Survival (PFS) | 5.9 (5.5 to 6.7) | 3.9 (3.7 to 5.3) | 5.0 (3.8 to 5.6) | 4.9 (3.6 to 5.6) |
Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date.
| months | Wild-type KRAS - Panitumumab Plus FOLFIRI | Wild-type KRAS - FOLFIRI Alone | Mutant KRAS - Panitumumab Plus FOLFIRI | Mutant KRAS - FOLFIRI Alone |
|---|---|---|---|---|
| Overall Survival | 14.5 (13.0 to 16.0) | 12.5 (11.2 to 14.2) | 11.8 (10.4 to 13.3) | 11.1 (10.3 to 12.4) |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.
| percentage of participants | Wild-type KRAS - Panitumumab Plus FOLFIRI | Wild-type KRAS - FOLFIRI Alone | Mutant KRAS - Panitumumab Plus FOLFIRI | Mutant KRAS - FOLFIRI Alone |
|---|---|---|---|---|
| Percentage of Participants With an Objective Response | 35.35 (29.92 to 41.08) | 9.82 (6.63 to 13.89) | 13.36 (9.26 to 18.43) | 13.92 (9.78 to 19.00) |
Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.
| months | Wild-type KRAS - Panitumumab Plus FOLFIRI | Wild-type KRAS - FOLFIRI Alone | Mutant KRAS - Panitumumab Plus FOLFIRI | Mutant KRAS - FOLFIRI Alone |
|---|---|---|---|---|
| Time to Disease Progression | 7.3 (5.9 to 7.5) | 5.3 (3.9 to 5.7) | 5.5 (4.5 to 5.7) | 5.5 (4.2 to 5.7) |
Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.
| months | Wild-type KRAS - Panitumumab Plus FOLFIRI | Wild-type KRAS - FOLFIRI Alone | Mutant KRAS - Panitumumab Plus FOLFIRI | Mutant KRAS - FOLFIRI Alone |
|---|---|---|---|---|
| Duration of Response | 7.6 (6.7 to 9.4) | 6.6 (5.7 to 10.4) | 6.0 (5.4 to 7.4) | 7.4 (4.0 to 8.1) |
A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"
| participants | Panitumumab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Any adverse event | 584 | 573 |
| Serious adverse event | 232 | 175 |
| Leading to discontinuation of any study drug | 123 | 64 |
| Treatment-related adverse event (TRAE) | 577 | 542 |
| Serious treatment-related adverse event | 124 | 90 |
| TRAE leading to discontinuation of any study drug | 97 | 34 |
Collected over The median treatment period was approximately 6.2 months in the Panitumumab plus FOLFIRI arm, and 4.7 months in the FOLFIRI Alone arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus FOLFIRI | — | 232/587 (39.5%) | 575/587 (98%) |
| FOLFIRI Alone | — | 175/594 (29.5%) | 546/594 (91.9%) |
| Event | Panitumumab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 33/587 | 23/594 |
| PyrexiaGeneral disorders | 24/587 | 16/594 |
| DehydrationMetabolism and nutrition disorders | 20/587 | 11/594 |
| VomitingGastrointestinal disorders | 17/587 | 13/594 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 17/587 | 10/594 |
| Febrile neutropeniaBlood and lymphatic system disorders | 11/587 | 16/594 |
| Abdominal painGastrointestinal disorders | 12/587 | 13/594 |
| NauseaGastrointestinal disorders | 12/587 | 5/594 |
| NeutropeniaBlood and lymphatic system disorders | 6/587 | 12/594 |
| Colorectal cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/587 | 10/594 |
| Event | Panitumumab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 372/587 | 321/594 |
| RashSkin and subcutaneous tissue disorders | 330/587 | 38/594 |
| NauseaGastrointestinal disorders | 276/587 | 269/594 |
| NeutropeniaBlood and lymphatic system disorders | 207/587 | 209/594 |
| FatigueGeneral disorders | 203/587 | 186/594 |
| VomitingGastrointestinal disorders | 154/587 | 162/594 |
| AnorexiaMetabolism and nutrition disorders | 146/587 | 93/594 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 141/587 | 3/594 |
| ConstipationGastrointestinal disorders | 139/587 | 125/594 |
| AlopeciaSkin and subcutaneous tissue disorders | 124/587 | 136/594 |
| Age, Continuous(years) | Panitumumab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| Mean | 60.2 ± 10.5 | 60.9 ± 10.6 | 60.6 ± 10.5 |
| Sex: Female, Male(Participants) | Panitumumab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| Female | 245 | 219 | 464 |
| Male | 346 | 376 | 722 |
| Race/Ethnicity, Customized(participants) | Panitumumab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| White or Caucasian | 568 | 569 | 1137 |
| Black or African American | 4 | 5 | 9 |
| Hispanic or Latino | 2 | 3 | 5 |
| Asian | 2 | 3 | 5 |
| Japanese | 9 | 11 | 20 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Aborigine | 2 | 1 | 3 |
| Other | 3 | 2 | 5 |
| KRAS Status(participants) | Panitumumab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| Wild-type KRAS | 303 | 294 | 597 |
| Mutant KRAS | 238 | 248 | 486 |
| Unevaluable KRAS | 50 | 53 | 103 |
| Prior Oxaliplatin Exposure for mCRC(participants) | Panitumumab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| No | 179 | 182 | 361 |
| Yes | 412 | 413 | 825 |
| Prior Bevacizumab Exposure for mCRC(participants) | Panitumumab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| No | 480 | 483 | 963 |
| Yes | 111 | 112 | 223 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Panitumumab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| Grade 0 or 1 | 564 | 565 | 1129 |
| Grade 2 | 27 | 30 | 57 |
No study locations are listed for this record.
Ran from Jun 2006 to primary completion in Apr 2009, 33 months.
Results were first posted in May 2014, 5 years 1 month after primary completion. A results delay was requested in Jul 2010.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 33 months is below that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab